Project

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic HormoneSensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Ongoing - recruitment closed · 2020 until 2030

Omlin Aurelius, Rothermundt Christian, Aeppli Stefanie